论文部分内容阅读
目的:探讨儿童炎症性肠病（IBD）患者生长迟缓的发生率、临床特征及危险因素。方法:采用横断面研究方法。2019年4月至5月在全国8个IBD医疗中心患者微信群内招募并筛选确诊年龄小于18岁的IBD患者，通过问卷调查收集人口学、临床及生长相关的资料，计算两个时间点（诊断时和调查时）生长迟缓的发生率。根据调查时是否存在生长迟缓，将患者分为生长迟缓组和无生长迟缓组，并采用单因素和多因素Logistic回归分析生长迟缓的危险因素。结果:纳入97例IBD患者，其中溃疡性结肠炎（UC）8例，克罗恩病（CD）89例。UC患者均无生长迟缓。89例CD患者中，男性48例，女性41例；年龄15.5（1.0，21.0）岁。调查时生长迟缓患者共14例（15.7%），设为生长迟缓组，无生长迟缓者75例，设为无生长迟缓组；诊断时生长迟缓发生率为19.0%（16/84）。单因素分析显示，与无生长迟缓患者比较，生长迟缓患者诊断年龄更低[5.0（1.0，13.8）岁比14.0（12.0，16.0）岁，n P = 0.003]，疾病活动度更重（n P = 0.006），急性消化道穿孔比例更高[28.6%（4/14）比2.7%（2/75），n P = 0.005）]，使用糖皮质激素的患者比例更高[64.3%（9/14）比33.3%（25/75），n P = 0.029）]，糖皮质激素使用时间更长[1.5（0，6.5）个月比0（0，3.0）个月，n P = 0.040]，而使用生物制剂的患者比例更低[42.9%（6/14）比80.0%（60/75），n P = 0.010]，生物制剂使用时间更短[0（0，6.3）个月比7.0（1.0，12.0）个月，n P = 0.006]。多因素Logistic回归分析显示，诊断年龄为CD患者生长迟缓的独立危险因素（n OR = 6.909，95%n CI：1.250 ~ 38.195，n P = 0.027）。n 结论:诊断年龄低的儿童起病IBD患者较易发生生长迟缓，临床应予以重视。“,”Objective:To investigate the incidence, clinical characteristics and risk factors of growth retardation in pediatric onset IBD patients.Methods:A cross-sectional study was conducted. IBD patients with the age at diagnosis younger than 18 years old were recruited and screened in the Wechat group of patients in 8 IBD medical centers across the country. Demographic, clinical and growth-related data were collected through questionnaire survey, and the incidences of growth retardation at the time of diagnosis and investigation were calculated. According to whether there was growth retardation at the time of investigation, the patients were divided into growth retardation group and non-growth retardation group. The influencing factors of growth retardation were analyzed by the univariate analysis and multivariate Logistic regression analysis.Results:A total of 97 patients were involved including 8 ulcerative colitis (UC) and 89 Crohn′s disease (CD). There was no growth retardation in UC patients. Among 89 patients with CD, there were 48 males and 41 females, and the age was 15.5 (1.0, 21.0) years old. At the time of investigation, 14 patients (15.7%) with growth retardation were set as the growth retardation group, and 75 without growth retardation were set as the non-growth retardation group. The incidence of growth retardation was 19.0% (16/84) at the time of diagnosis. Univariate analysis results showed that compared with non-growth retardation group, patients in growth retardation group had lower diagnostic age [5.0 (1.0, 13.8) years old vs. 14.0 (12.0, 16.0) years old, n P = 0.003], severer disease activity (n P = 0.006), higher proportion of acute gastrointestinal perforation [28.6% (4/14) vs. 2.7% (2/75), n P = 0.005], higher proportion of patients in using glucocorticoids [64.3% (9/14) vs. 33.3% (25/75), n P = 0.029), and longer time of using glucocorticoids [1.5 (0, 6.5) months vs. 0 (0, 3.0) months, n P = 0.040], while the proportion of patients using biological agents was lower [42.9% (6/14) vs. 80.0% (60/75), n P = 0.010], and the time of using biological agents was shorter [0 (0, 6.3) months vs. 7.0 (1.0, 12.0) months, n P = 0.006]. Logistic regression analysis revealed that the age at diagnosis of CD was still a risk factor for growth retardation after correcting other factors (n OR = 6.909, 95%n CI: 1.250-38.195, n P = 0.027) .n Conclusion:The pediatric onset IBD patients with low diagnostic age are prone to growth retardation, which should be paid attention to.